Abstract
Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.
Original language | English (US) |
---|---|
Pages (from-to) | 113-115 |
Number of pages | 3 |
Journal | Investigational New Drugs |
Volume | 20 |
Issue number | 1 |
DOIs | |
State | Published - Apr 6 2002 |
Keywords
- Amonafide
- Central nervous system tumors
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)